Evaluation of Antibodies to Human Papillomavirus as Prognostic Markers in Cervical Cancer Patients
- 1 May 2002
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 85 (2) , 333-338
- https://doi.org/10.1006/gyno.2002.6628
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- The presence of HPV DNA in cervical cancer: Correlation with clinico-pathologic parameters and prognostic significance: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz UniversityInternational Journal of Gynecologic Cancer, 2001
- The serological response to papillomavirusesSeminars in Cancer Biology, 1999
- Human papillomavirus is a necessary cause of invasive cervical cancer worldwideThe Journal of Pathology, 1999
- Human papillomavirus genotype as a major determinant of the course of cervical cancer.Journal of Clinical Oncology, 1998
- Human papillomavirus DNA and antibodies to human papillomaviruses 16 E2, L2, and E7 peptides as predictors of survival in patients with squamous cell cervical cancer.Journal of Clinical Oncology, 1997
- The Oncogenic Role of Human Papillomavirus ProteinsCritical Reviews™ in Oncogenesis, 1996
- Serum antibody responses against human papillomavirus in relation to tumor characteristics, response to treatment, and survival in carcinoma of the uterine cervixCancer Immunology, Immunotherapy, 1995
- Antibodies to human papillomavirus type 16 E7 related to clinicopathological data in patients with cervical carcinoma.Journal of Clinical Pathology, 1995
- Cell cycle targets of the DNA tumor virusesCurrent Opinion in Genetics & Development, 1994
- Association of Human Papillomavirus Types 16 and 18 E6 Proteins with p53Science, 1990